SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

Recursion, Exscientia, and AI drug discovery’s moment of truth Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger.

Recursion Pharmaceuticals RXRX is gearing up to announce its quarterly earnings on Tuesday, 2025-08-05. Here's a quick overview of what investors should know before the release. Analysts are ...

Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart.

Is Recursion Pharma a buy because of Nvidia’s endorsement? Indeed, Nvidia’s bet on Recursion is notable, but despite the stake and collaboration, the name isn’t without its fair share of risks.

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to Benzinga Pro. The company reported a second-quarter loss of 41 cents per ...

The Motley Fool has a disclosure policy. Why Recursion Pharmaceuticals Stock Tanked on Tuesday Person in a lab gazing into a microscope.© Getty Images ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to beat earnings when it reports second-quarter 2025 results on Aug. 5 ...

Explore RXRX's upcoming H2'25 trial updates for REC-4881 in familial adenomatous polyposis and REC-617.